Trulieve Cannabis' (TRLV) Overweight Rating Reiterated at Cantor Fitzgerald

Trulieve Cannabis (NYSE:TRLV - Get Free Report)'s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald's target price suggests a potential upside of 37.70% from the company's previous close.

Several other research analysts also recently issued reports on the company. Wall Street Zen downgraded Trulieve Cannabis from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Trulieve Cannabis in a report on Friday, September 11th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Trulieve Cannabis presently has a consensus rating of "Hold" and a consensus price target of $15.00.

Trulieve Cannabis Trading Down 1.0%

Shares of NYSE TRLV opened at $10.89 on Friday. The firm has a market cap of $2.10 billion and a PE ratio of 99.03. Trulieve Cannabis has a 52 week low of $4.62 and a 52 week high of $13.28. The company has a 50-day simple moving average of $11.15. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.98 and a current ratio of 5.94.

Trulieve Cannabis (NYSE:TRLV - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.05. Trulieve Cannabis had a negative net margin of 41.55% and a negative return on equity of 4.24%. The company had revenue of $271.00 million during the quarter, compared to analysts' expectations of $268.82 million. As a group, research analysts expect that Trulieve Cannabis will post 0.31 earnings per share for the current year.

Institutional Trading of Trulieve Cannabis

A number of hedge funds have recently bought and sold shares of TRLV. Marion Wealth Management acquired a new position in Trulieve Cannabis in the 3rd quarter valued at $109,000. PFS Partners LLC purchased a new position in shares of Trulieve Cannabis during the 3rd quarter worth $33,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in shares of Trulieve Cannabis during the third quarter worth $770,000.

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes and sells medical and adult-use cannabis products. Its offerings include flower, pre-rolls, concentrates, vaporizers, edibles, tinctures, capsules and topical products, sold through retail dispensaries and other approved channels under brands such as Trulieve, Cultivar Collection, Muse, Roll One and Alchemy.

Founded in 2015, Trulieve initially built its business around Florida's medical cannabis market and later expanded into additional U.S.